January 10, 2020
Silva MA et al. J Pathol Clin Res 2020;6(2):124-137.
Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells.
You might also be interested by
Press Releases
Caprion-HistoGeneX expands its histological biomarker franchise by joining forces with Mosaic Laboratories
January 12, 2021
Histopathology
More infoScientific Publications
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
May 15, 2019
Histopathology
More infoScientific Publications
Digital pathology in immuno-oncology – a roadmap for clinical development
January 12, 2017
Histopathology
More info